Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Antibiotics regulate bacterial diversification, niche expansion and evolution under primordial conditions.

Biochimie·2026

Same author

Recent advances in site-specific modifications of peptides and proteins.

Chemical science·2026

Same author

Chemical Strategy and AI-Enabled Peptide Vaccine Development.

JACS Au·2026

Same author

Disproportionation of elemental sulfur by <i>Exiguobacterium</i> from marine sediment.

ISME communications·2025

Same author

Facial paint contamination: A new removal technique by using paraffin oil.

Medicine·2025

Same author

Recent developments in late-stage protein modification.

Chemical communications (Cambridge, England)·2025

Search research articles

Related Experiment Video

Updated: May 10, 2025

A Tripeptide-Stabilized Nanoemulsion of Oleic Acid

A Tripeptide-Stabilized Nanoemulsion of Oleic Acid

Published on: February 27, 2019

Peptide-Based Strategies in PLGA-Enhanced Tumor Therapy.

Hong-Lin Han¹, Jing-Yun Su¹, Xiao-Huan Zhao²

¹Key Laboratory of Bioorganic Phosphorus Chemistry and Chemical Biology (Ministry of Education), Department of Chemistry, Tsinghua University, Beijing, China.

Journal of Peptide Science : an Official Publication of the European Peptide Society

|April 24, 2025

Summary

This summary is machine-generated.

Peptide-functionalized poly(lactic-co-glycolic acid) (PLGA) systems enhance peptide therapeutics for cancer treatment by improving stability and delivery. These systems offer precise, localized drug release, overcoming key challenges in peptide-based cancer therapy.

Keywords:

PLGA nanoparticles controlled drug release peptide‐based therapeutics targeted drug delivery

More Related Videos

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

Synthesis and Characterization of Placental Chondroitin Sulfate A plCSA-Targeting Lipid-Polymer Nanoparticles

Synthesis and Characterization of Placental Chondroitin Sulfate A plCSA-Targeting Lipid-Polymer Nanoparticles

Published on: September 18, 2018

Related Experiment Videos

Last Updated: May 10, 2025

A Tripeptide-Stabilized Nanoemulsion of Oleic Acid

A Tripeptide-Stabilized Nanoemulsion of Oleic Acid

Published on: February 27, 2019

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

Synthesis and Characterization of Placental Chondroitin Sulfate A plCSA-Targeting Lipid-Polymer Nanoparticles

Synthesis and Characterization of Placental Chondroitin Sulfate A plCSA-Targeting Lipid-Polymer Nanoparticles

Published on: September 18, 2018

Area of Science:

Biomaterials Science
Nanotechnology
Cancer Therapeutics

Background:

Peptide therapeutics show promise for cancer treatment due to specificity and low toxicity.
Enzymatic degradation and poor bioavailability limit clinical applications of peptide drugs.
Peptide-functionalized poly(lactic-co-glycolic acid) (PLGA) systems offer enhanced stability, sustained release, and targeted delivery.

Purpose of the Study:

To review the synergistic integration of peptides with PLGA systems for cancer therapy.
To address challenges associated with peptide-based therapeutics.
To highlight the diverse applications of peptide-functionalized PLGA systems in cancer treatment.

Main Methods:

Review of existing literature on peptide-functionalized PLGA systems in cancer therapy.
Analysis of strategies for chemotherapy, immunotherapy, and targeted delivery.
Discussion of tumor microenvironment (TME)-responsive release mechanisms.

Main Results:

Peptide-functionalized PLGA systems enhance stability and bioavailability of peptide therapeutics.
These systems demonstrate versatility in chemotherapy (disrupting tumor pathways, inhibiting angiogenesis) and immunotherapy (stimulating immune responses, acting as checkpoint inhibitors).
Enhanced permeability and retention (EPR) effect facilitates tumor accumulation, with TME-responsive systems enabling controlled, localized drug release.

Conclusions:

Peptide-functionalized PLGA systems represent a transformative platform for precise cancer therapy.
Integration of peptides with PLGA overcomes limitations of traditional peptide drugs.
These systems offer a versatile approach combining innovative delivery with potent therapeutic agents for improved cancer treatment outcomes.